



Evaluating insecticide resistance across African districts to aid malaria control decisions

Catherine L. Moyes^{a,1}, Duncan K. Athinya^b, Tara Seethaler^c, Katherine E. Battle^d, Marianne Sinka^e, Melinda P. Hadi^f, Janet Hemingway^{g,1}, Michael Coleman^g, and Penelope A. Hancock^{a,1}

^aBig Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford OX3 7LF, United Kingdom; ^bVestergaard Frandsen (EA) Ltd, Nairobi, Kenya; ^cClinton Health Access Initiative, Boston, MA 02127; ^dInstitute for Disease Modeling, Bellevue, WA 98005; ^eDepartment of Zoology, University of Oxford, Oxford OX1 3RB, United Kingdom; ^fVestergaard SA, CH – 1003 Lausanne, Switzerland; and ^gDepartment of Vector Biology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, United Kingdom

Contributed by Janet Hemingway, July 15, 2020 (sent for review May 6, 2020); reviewed by Thomas S. Churcher and Abdoulaye Diabaté

Malaria vector control may be compromised by resistance to insecticides in vector populations. Actions to mitigate against resistance rely on surveillance using standard susceptibility tests, but there are large gaps in the monitoring data across Africa. Using a published geostatistical ensemble model, we have generated maps that bridge these gaps and consider the likelihood that resistance exceeds recommended thresholds. Our results show that this model provides more accurate next-year predictions than two simpler approaches. We have used the model to generate district-level maps for the probability that pyrethroid resistance in *Anopheles gambiae* s.l. exceeds the World Health Organization thresholds for susceptibility and confirmed resistance. In addition, we have mapped the three criteria for the deployment of piperonyl butoxide-treated nets that mitigate against the effects of metabolic resistance to pyrethroids. This includes a critical review of the evidence for presence of cytochrome P450-mediated metabolic resistance mechanisms across Africa. The maps for pyrethroid resistance are available on the IR Mapper website, where they can be viewed alongside the latest survey data.

pyrethroid | malaria control | insecticide resistance management | insecticide resistance | metabolic resistance

Malaria control is primarily achieved by targeting the mosquito vectors that transmit the malaria parasite. In sub-Saharan Africa, vector control relies heavily on insecticides integrated into bednets or applied to indoor walls (1). This means that vector control, and thus malaria control, may be compromised by resistance to these insecticides in vector populations (2).

The World Health Organization (WHO) published a *Global Plan for Insecticide Resistance Management in Malaria Vectors* (hereafter the “Global Plan for IRM”) that outlines best-practice strategies for preserving or prolonging the effectiveness of the insecticides used for malaria control, based on the best available evidence at the time (3). Recommended actions depend on surveillance of insecticide resistance measured by standard insecticide susceptibility tests as summarized in Table 1. These actions rely on the availability of insecticides with distinct modes of action that can be either rotated annually, applied in spatial mosaics, used in combinations of different interventions, or applied as mixed formulations. For indoor residual spraying (IRS), four neurotoxic insecticide classes have been used over many decades (carbamates, organochlorines, organophosphates, and pyrethroids) and, more recently, a neonicotinoid has also been approved (4). In contrast, the range of insecticides recommended for insecticide-treated nets is more restricted and until 2016 was limited to pyrethroids, either alone or in combination with piperonyl butoxide (PBO), a synergist that counters P450 cytochrome-mediated resistance to pyrethroids but does not have an impact in the absence of this mechanism of resistance.

Long-lasting insecticide-treated nets (LLINs) are the primary recommended intervention for vector control and the use of pyrethroid-treated nets has underpinned the reductions in

malaria prevalence from 2000 to 2015 (1, 5). For this reason, the Global Plan for IRM places particular emphasis on prolonging the effectiveness of pyrethroids in vector control. All currently recommended insecticide-treated net formulations use pyrethroids, but dramatic increases in pyrethroid resistance in the major African malaria vectors have occurred from 2005 to 2017 (4, 6). Fortunately, three partner compounds have recently been introduced to net formulations. WHO prequalification status has been awarded to LLINs impregnated with a combination of the pyrethroid α -cypermethrin, and the pyrrole chlorfenapyr (7) and to LLINs impregnated with α -cypermethrin and the insect growth regulator pyriproxyfen (8). LLINs treated with a pyrethroid (α -cypermethrin, deltamethrin, or permethrin) in combination with PBO first became available 10 years ago, and in 2017 the WHO gave pyrethroid-PBO nets an interim endorsement as a new vector control class pending further review of the epidemiological data from randomized control trials (9). The WHO’s Global Plan for IRM covers the use of alternative insecticide classes but does not provide guidelines for use of products that contain a synergist that counters a specific mechanism of resistance. The WHO, therefore, published the *Conditions for Deployment of Mosquito Nets Treated with a Pyrethroid and Piperonyl*

Significance

Malaria control in Africa largely relies on the use of insecticides to prevent mosquitoes from transmitting the malaria parasite to humans; however, these mosquitoes have evolved resistance to these insecticides. To manage this threat to malaria control, it is vital that we map locations where the prevalence of resistance exceeds thresholds defined by insecticide resistance management plans. A geospatial model and data from Africa are used to predict locations where thresholds of resistance linked to specific recommended actions are exceeded. This model is shown to provide more accurate next-year predictions than two simpler approaches. The model is used to generate maps that aid insecticide resistance management planning and that allow targeted deployment of interventions that counter specific mechanisms of resistance.

Author contributions: C.L.M. and P.A.H. designed research; C.L.M. and P.A.H. performed research; C.L.M., J.H., and P.A.H. analyzed data; C.L.M., D.K.A., T.S., K.E.B., M.S., M.P.H., J.H., M.C., and P.A.H. wrote the paper; D.K.A. and M.P.H. advised on tools for decision makers; and T.S. and K.E.B. advised on decision making for malaria control.

Reviewers: T.S.C., Imperial College London; and A.D., Institut de Recherche en Science de la Santé.

Competing interest statement: D.K.A. and M.P.H. are employees of Vestergaard SA.

This open access article is distributed under [Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 \(CC BY-NC-ND\)](https://creativecommons.org/licenses/by-nc-nd/4.0/).

¹To whom correspondence may be addressed. Email: catherinemoyes@gmail.com, janet.hemingway@lstmed.ac.uk, or penny.hancock@bdi.ox.ac.uk.

This article contains supporting information online at <https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2006781117/-DCSupplemental>.

First published August 25, 2020.

Table 1. Recommendations regarding insecticide choice for LLINs and IRS

		2: What is the resistance status (susceptibility test result)?		
		Pyrethroid resistant (<90% mortality)		
		No cytochrome P450-mediated resistance or no data (<10% increase in mortality with PBO)	Cytochrome P450-mediated resistance (≥10% increase in mortality with PBO)	
1. What is the primary intervention currently in use?	Susceptible (>98% mortality)		(10–80% mortality without PBO)	(Mortality without PBO not 10–80%)
LLINs	Continue monitoring using susceptibility tests and, if cases are increasing, ensure timely replacement of worn-out nets and assure the quality and extent of LLIN coverage.	In addition to LLINs, introduce focal IRS in annual rotations, at least in areas of greatest concern, and use nonpyrethroid active ingredients when they become available, providing this does not compromise coverage.	Consider switching to PBO-treated LLINs. and/or introducing focal IRS in annual rotations, at least in areas of greatest concern, and using nonpyrethroid active ingredients, providing this does not compromise coverage.	Introduce focal IRS in annual rotations, at least in areas of greatest concern, and use nonpyrethroid active ingredients, providing this does not compromise coverage.
IRS	Preemptive rotation of insecticide classes with confirmed susceptibility.	Switch away from current insecticide and rotate alternative compounds.		

This is an abridged summary of the recommendations in tables 4 and 5 of the Global Plan for IRM and accompanying text, the thresholds defined in the WHO's Test Procedures for Insecticide Resistance Monitoring, and the recommendations outlined in the Conditions for Deployment of PBO-treated Nets (3, 10, 12). The recommendations linked to the presence of *kdr* mechanisms have been excluded for reasons of brevity and because these are not materially different from "resistance without mechanism data" or "no cytochrome P450-mediated resistance." The threshold values for susceptibility test results are given in parentheses.

Butoxide (hereafter the "Conditions for Deployment of PBO-treated Nets") in 2017 (10, 11). These guidelines also recommend actions that depend on surveillance of insecticide resistance measured by standard insecticide susceptibility tests (Table 1).

Although the current recommendations in the Global Plan for IRM and the Conditions for Deployment of PBO-treated Nets rely on surveillance of insecticide resistance measured by standard insecticide susceptibility tests (12, 13), a 2017 review of implementation of the Global Plan for IRM found monitoring was inadequate and inconsistent in most settings (14, 15). A review of the data available today shows that this is still true (Fig. 1). A total of 1,550 results from standard pyrethroid susceptibility tests using mosquitoes from the *Anopheles gambiae* complex or the *Anopheles funestus* subgroup are available for

2015 to 2017, from a published database (15). This equates to data for 362 out of 3,323 malaria-endemic second-order administrative divisions (hereafter "districts"); thus, 89% of these districts did not have surveillance data for these years (Fig. 1A). The data behind the WHO's Malaria Threats website are not available, so the number of data points is unknown, but the gaps in these data can be visualized (Fig. 1B). The data behind the IR Mapper website can also be visualized online and the number of data points available for the same pyrethroid tests from 2015 to 2017 is 1,817 (Fig. 1C).

To address these issues, we propose using the results of a recently developed geostatistical ensemble model that was fitted to a published series of susceptibility test surveillance data covering 31 African countries and spanning a period of 13 years (6, 15). The geostatistical ensemble model accounts for noise in the




Fig. 1. Gaps in the available insecticide resistance surveillance data from standard WHO and CDC tests using the *An. gambiae* complex and *An. funestus* subgroup. (A) Districts with susceptibility test (bioassay) results for 2015 to 2017 from a published susceptibility test dataset that collated data from routine monitoring by agencies such as the President's Malaria Initiative (PMI) and from research groups in Africa and was subject to rigorous quality-assurance processes (15). Ninety-four percent (3,136/3,323) of malaria-endemic second-order administrative divisions do not have any data for insecticide resistance in this year and 89% (2,962/3,323) do not have any data in this year or the two preceding years. (B) Data shown on the WHO Malaria Threats website for the years 2015 to 2019 (accessed 9 December 2019) (16). (C) Data shown on the IR Mapper website for the years 2015 to 2019 (accessed 9 December 2019) obtained from published articles and PMI surveillance (17).

susceptibility test data and provides a set of 13 fine-resolution, annual maps for each year from 2005 to 2017, representing the mean prevalence of resistance in *An. gambiae* s.l. to each of the pyrethroids most commonly used in LLINs (α -cypermethrin, deltamethrin, permethrin, and λ -cyhalothrin) and resistance to DDT. These maps provide values in data-sparse areas and are potentially a powerful tool for use when considering the choice of insecticide for malaria vector control. In addition to gaps in the surveillance data, decision makers are often faced with data that are not up-to-date (Fig. 1). Here we demonstrate the capacity of the geostatistical ensemble model to predict pyrethroid resistance 1 year ahead, outperforming simple district-level data summaries. Tools for decision makers need to incorporate threshold values that are linked to specific actions (Table 1) and provide information about the uncertainty around the predictions for achieving these thresholds. We demonstrate how the published geostatistical ensemble model can be used to calculate the probability of these thresholds' being met. In addition to the key insecticide susceptibility thresholds defined by resistance management plans, the deployment of PBO-treated nets requires evidence for the presence cytochrome P450-mediated mechanisms of resistance (Table 1) (10). Here we therefore also review and map the evidence for presence of these mechanisms of resistance. Finally, we present a set of maps that show the probability of exceeding thresholds linked to recommended actions at a district scale, that is, the spatial resolution commonly used for operational decisions.

Materials and Methods

Identifying Gaps in the Surveillance Data. Standard susceptibility test data for pyrethroid resistance in all African malaria vectors were extracted from the largest publicly available database of insecticide resistance data (15) and processed in QGIS 3.4.12 software. Each data point was linked to a year and to either the geographical coordinates for a precise collection location or an identifier for the administrative unit where the mosquitoes were collected. These two pieces of information were used to calculate the number of data points in each year in each second-order administrative unit (hereafter referred to as districts). Each district was also classified as malaria-endemic or not by overlaying the administrative unit layer with raster maps of *Plasmodium falciparum* and *Plasmodium vivax*. Nonendemic areas were discarded and the proportion of endemic districts with susceptibility test data for each year was calculated. The resulting map is presented alongside the most recent data from the IR Mapper and Malaria Threats websites (16, 17).

Existing Geostatistical Ensemble Model Used in This Study. This study used the outputs from a published Bayesian geostatistical ensemble model (6), which were used here to generate the cumulative probability maps described below. Further, the model was rerun to test its ability to provide next-year predictions. The ensemble model has been described in full by Hancock et al. (6). Briefly, the Bayesian geostatistical ensemble model was fitted to over 6,000 data points from susceptibility tests that exposed *An. gambiae* s.l. mosquitoes to four pyrethroids and DDT. The model leveraged 1) associations between resistance and potential explanatory variables such as LLIN coverage, IRS coverage, and agriculture (18–20) and 2) spatial patterns in the resistance data. This ensemble model generated a posterior distribution of predictions for every cell in a fine resolution (2.5 arcmin, ~5-km) grid. Validation of the outputs by Hancock et al. (6) using withheld data (out-of-sample validation) showed that the ensemble model produced robust predictions within the area and time frame for which data on pyrethroid resistance were available. For the current study we used the model output for mortality after deltamethrin exposure in a standard susceptibility test. We selected deltamethrin resistance because this pyrethroid has the largest volume of susceptibility test data available, and the deltamethrin resistance outputs had the narrowest credible intervals (6). There are, however, strong associations among the patterns of resistance to all four pyrethroids (α -cypermethrin, deltamethrin, permethrin, and λ -cyhalothrin) (21).

Calculating District-Level Resistance Means. To generate maps of mean mortality across each district, \bar{m}_j^D , we used the mean values produced by the model for every grid cell, weighted using values for *An. gambiae* s.l. habitat

suitability that are available at the same resolution of ~5 km as the resistance values (22):

$$\bar{m}_j^D = \sum_{i \in j} \bar{m}_{ij}^D w_{ij}, \quad [1]$$

where \bar{m}_{ij}^D is the predicted mean mortality for deltamethrin in grid cell i and w_{ij} is relative habitat suitability.

Calculating the Probability of a District Exceeding a Set Mortality Threshold. We created a series of maps for the probability of meeting the resistance thresholds used in management decision making (Table 1) at the district level. We used the full posterior distributions of resistance predictions made by the geostatistical ensemble model to produce maps of 1) the probability that the mean mortality was $\geq 98\%$ (the WHO threshold for "susceptibility") and 2) the probability that the mean mortality was $< 90\%$ (the WHO threshold for "resistance").

The posterior distribution of the weighted district mean (Eq. 2) was calculated using $k = 1,000$ draws from the posterior distribution of the predicted resistance in each pixel, \check{m}_{ijk}^D , and then calculating a weighted mean, \check{m}_{jk}^D , across each district for each posterior draw:

$$\check{m}_{jk}^D = \sum_{i \in j} \check{m}_{ijk}^D w_{ij}. \quad [2]$$

The cumulative probabilities 1 and 2 across all posterior draws were then calculated. A wider range of thresholds is useful to visualize the areas worst affected by resistance so we also calculated the cumulative probabilities that each district has a mean mortality of $< 80\%$, $< 70\%$, $< 60\%$, $< 50\%$, $< 40\%$, $< 30\%$, $< 20\%$, and $< 10\%$.

Assessing Whether the Criteria for Deployment of PBO-Treated Nets Have Been Met. Deployment of pyrethroid LLINs treated with PBO is currently recommended in places that meet all of the following criteria: 1) there is pyrethroid resistance that 2) results in 10 to 80% mortality in a susceptibility test and 3) is conferred (at least in part) by a monooxygenase-based resistance mechanism (that is, elevated levels of cytochrome P450) (10). To test which districts meet the first two criteria, we used the full posterior distributions of predictions to calculate the probability of the mean mortality being 10 to 80% for each district, as described above for the 98% and 90% threshold maps.

To assess the third criterion, results of paired standard pyrethroid susceptibility tests conducted from 2005 to 2018 with and without PBO were extracted from a published database (15). The WHO protocol for these tests defines a difference of $\geq 10\%$ as evidence for the presence of cytochrome P450-mediated mechanisms of resistance (12). The mortality obtained with the addition of the synergist was plotted against mortality after exposure to the pyrethroid alone, and the data were divided into those pairs with a difference of $\geq 10\%$ mortality and those with a difference of $< 10\%$ mortality. Each data point had a link to geographical coordinates for the location of mosquito collection and these were used to associate each data point with a second-order administrative unit using the QGIS 3.4.12 software. We used these data to generate a map that classified each district tested according to whether it had evidence for presence of this mechanism, or for its absence, or no evidence. In some instances, more than one data point was linked to a single district. If a single district had a test result(s) that showed the presence of this mechanism, as well as a test result(s) that showed an absence of this mechanism, then the district was classified as having evidence for the presence of cytochrome P450-mediated mechanisms of resistance.

Assessing the Approaches to Address the Time Lag between Vector Sampling and Data Availability. One limitation of the available information on resistance, whether it consists of susceptibility test data or modeled predictions for mean test results, is the time lag between 1) mosquito specimens being collected in the field and tested for resistance, and 2) the data being checked, compiled, and made available. The most up-to-date information available is inevitably out-of-date once it has been cleaned and collated (Fig. 1), but decision makers require information on the current situation. To address the scenario where susceptibility test data and modeled maps are available for each year up to and including the preceding year, but no information is available for the current year, we tested three approaches to determine which provides the most robust values for the current year. To do this, we compared our pyrethroid resistance maps to the observed mortality values 1 year ahead. We also compared the values obtained using two simpler methods to the observed mortality values 1 year ahead. The two simpler

methods involved calculating 1) the mean and 2) the minimum value of the susceptibility test results from the preceding year for each district. The minimum mortality value equates to the maximum prevalence of resistance; thus, in this approach, we assume that mortality is decreasing over time, that is, resistance is increasing. Each of these three approaches uses susceptibility test data from vector populations collected in the preceding year(s).

We assessed accuracy using next-year out-of-sample validation. For example, we used the geostatistical ensemble modeling approach described in Hancock et al. (6) to predict resistance based on a subset of the susceptibility test data spanning the time period 2010 to 2014, and compared the predictions for 2014 to the withheld test data available for 2015. Similarly, values for 2015 and 2016 were generated using models fitted to data subsets spanning the time periods 2010 to 2015 and 2010 to 2016 then compared to the observed data for 2016 and 2017, respectively. For values calculated using simpler district-level data summaries, we produced summaries of the susceptibility test data available for each district for the current year (2014, 2015, and 2016 individually) and then compared these to the next-year observed values for 2015, 2016, and 2017, respectively.

We compared the root-mean-square error (RMSE) across each of the three methods, for each of the three years predicted, for each geographical region (west and east Africa) to give six comparisons of predictive performance.

The geostatistical ensemble model also has the advantage of being able to provide modeled resistance values for districts in which no susceptibility test data for the current year are available. We calculated additional RMSE values comparing the modeled values for districts lacking current-year data with the next-year observed data for the same three pairs of consecutive years described above.

Overlaying the Geographical Distributions of *An. gambiae* s.l. and *An. funestus*.

The model described above predicted resistance in *An. gambiae* s.l. and this complex includes three widespread and important malaria vector species (*Anopheles arabiensis*, *Anopheles coluzzii*, and *An. gambiae*); however, *An. funestus* is also among the most important malaria vector species in Africa. When used in decision making, the model results generated by this study need to be considered alongside the respective distributions of the *An. gambiae* complex and *An. funestus*. To produce a single map of their respective distributions, predictive maps of the relative probability of occurrence of *An. gambiae* s.l. and *An. funestus* produced by Wiebe et al. (22) were converted to binary maps of presence and absence. The threshold predicted value from the *An. gambiae* s.l. map that captured 95% of the confirmed *An. gambiae* s.l. occurrences was identified and used to convert the continuous value maps into binary versions. The value of 95% of confirmed reports was selected to allow for errors in the confirmed reports, including errors in geopositioning of sites and errors in species identification. This process was repeated to generate a binary *An. funestus* map. The two binary data layers were then overlaid to provide a single map showing where both *An. gambiae* s.l. and *An. funestus* are likely to occur.

Results

Mapping the Probability of Districts Exceeding a Set Mortality Threshold. We provide a set of four district-level maps to assist decision makers in assessing pyrethroid resistance levels and evaluating each district with respect to the resistance thresholds stated in policy guidelines (Fig. 2). The four maps are the weighted mean resistance to deltamethrin for each district (Fig. 2A), the minimum mortality value (maximum resistance value) within each district (Fig. 2B), the probability of mortality to deltamethrin exceeding the WHO threshold for susceptibility (Fig. 2C), and the probability of mortality to deltamethrin exceeding the WHO threshold for confirmed resistance (Fig. 2D). Uncertainty in the district-level weighted means results from 1) heterogeneity in resistance within a district and 2) uncertainty in the model predictions for each location within the district. The map of minimum mortality values (Fig. 2B) provides an alternative summary statistic derived from the range of values predicted for locations across a district. In addition, we provide maps showing 1) heterogeneity in predicted mean mortality within each district and 2) uncertainty (95% credible intervals) in these predictions for west (SI Appendix, Fig. S1) and east Africa (SI Appendix, Fig. S2).

Published guidelines for insecticide resistance management provide clear threshold mortality values linked to recommended actions, but do not provide guidance on how to handle heterogeneity

within an area or uncertainty associated with either noisy field data or modeled predictions. While it is essential that uncertainty in district-level values is considered, viewing two or three or four maps alongside one another does not make decision making easy. For these reasons, we used the full set of predictions for every location within each district to calculate the probability of exceeding the published thresholds and generate a single map that communicates both the level of resistance and uncertainty in this value. The highest and lowest probability values, close to either 0 or 1, indicate certainty whereas intermediate probabilities, close to 0.5, indicate uncertainty (Fig. 2C and D). The results show that the threshold for susceptibility is highly unlikely to be met in any district in west or northeast Africa in 2017, but some districts in southern east Africa had probabilities of greater than 0.5 for meeting the susceptibility threshold (Fig. 2C). The threshold for confirmed resistance was highly likely to be met in most districts in west Africa in 2017, although some districts had an intermediate probability (Fig. 2D). In southern east Africa there was an intermediate or low probability of confirmed resistance.

These maps show resistance in the *An. gambiae* species complex and the distribution of this complex is shown in Fig. 3 alongside the predicted distribution for *An. funestus*. The results shown in Fig. 2 are relevant in all districts where *An. gambiae* s.l. is present, but in areas where *An. funestus* is also present (Fig. 3C) the results presented here should be considered alongside data on resistance in *An. funestus*.

The published threshold values that are linked to defined actions may change as new evidence becomes available. In addition, different thresholds may be selected where resources for more expensive interventions are limited, meaning that they can only be deployed in the worst-affected areas. For these reasons, maps for thresholds at every 10% interval were also generated and Movie S1 shows the probability of the mean mortality for a district being below each threshold value from 90 to 10% mortality.

Assessing Whether the Criteria for Deployment of PBO-Treated Nets Have Been Met.

Deployment of pyrethroid LLINs treated with PBO is currently recommended in places that meet all of the following criteria: 1) there is pyrethroid resistance that 2) results in 10 to 80% mortality in a susceptibility test and 3) is conferred (at least in part) by a monooxygenase-based resistance mechanism (this is, elevated levels of cytochrome P450), providing deployment does not compromise the levels of LLIN coverage that are achieved (10). The predicted probability that district-level mortality after deltamethrin exposure is 10 to 80% shows that deployment of these nets would currently be recommended in much of west and northeast Africa if cytochrome P450-mediated mechanisms of resistance were confirmed in these districts (Fig. 4A). Data for the presence of these mechanisms [defined by WHO in note i of figure 3.1 of the 2016 test procedures as a $\geq 10\%$ increase in susceptibility test mortality after the addition of PBO (12)] show that 79% (276/351) of the surveillance data for *An. gambiae* s.l. confirms the presence of these mechanisms, as does 94% (34/36) of the data for *An. funestus*. All 20 countries that were tested had evidence of elevated cytochrome P450 and the most recent evidence within each country was always for presence. The most recent year tested for these countries ranged from 2009 to 2018. When these data are plotted geographically, no obvious geospatial trends are apparent (Fig. 4B). It is also clear that there is variation in the increase achieved when PBO is used, from 10 to 100%, and considerable noise in the data (Fig. 4C).

There are substantial gaps in the susceptibility test data for cytochrome P450-mediated pyrethroid, with 96% (3,200/3,323) of malaria-endemic districts having no data in any year. Of the districts with data, 92% (114/123) meet the criteria for confirmed cytochrome P450-mediated pyrethroid resistance and 8% of the




Fig. 2. District-level deltamethrin resistance in local *An. gambiae* s.l. populations. (A) Predicted mean susceptibility test mortality for each district in 2017. (B) Predicted minimum susceptibility test mortality for each district in 2017. (C) Probability that mean susceptibility test mortality for the district is >98%, the definition of a “susceptible” population. (D) Probability that mean susceptibility test mortality for the district is <90%, the definition of a “resistant” population (22).

districts tested had no results that met these criteria. It is worth noting that 41 districts had multiple test results that gave conflicting outcomes of both greater than (presence) and less than (absence) 10% increase in mortality with the addition of PBO.

That is, the majority of districts (41/50) with one or more test results that did not meet the criteria to confirm cytochrome P450-mediated pyrethroid resistance also had a test result that did meet the criteria. This may indicate variation within district,




Fig. 3. The respective distributions of *An.gambiae* s.l. and *An. funestus*. (A) The predicted distribution of *An. gambiae* s.l. taken from Wiebe et al. (22). (B) The predicted distribution of *An. funestus* taken from Wiebe et al. (22). (C) The overlap in predicted presence (binary values) of *An.gambiae* s.l. and *An. funestus*.




Fig. 4. The probability of meeting the criteria for the deployment of PBO-treated nets. (A) The predicted probability that the mean mortality for a district is 10 to 80%. (B) Districts with surveillance data from paired standard susceptibility tests using a pyrethroid with and without the synergist PBO. (C) Plot of surveillance data from paired standard susceptibility tests using a pyrethroid with and without the synergist PBO showing the full variation in the results and key thresholds defined in WHO guidelines.

noise in the test data, or rapid spread of this mechanism of resistance. Either way, there is clearly little definitive evidence for absence of elevated cytochrome P450 in any of the regions tested.

Collectively these results show that much of west Africa is likely to have a level of pyrethroid resistance that meets two of the deployment criteria. Most of these districts do not have cytochrome P450 mechanism data; however, the closest data point to each district generally indicates presence of this mechanism. The area of northeast Africa with a high probability of meeting the criteria for the level of pyrethroid resistance has insufficient data to comment on whether elevated cytochrome P450 occurs.

Assessing Approaches to Address the Time Lag between Vector Sampling and Data Availability. The geostatistical ensemble model performed best according to the out-of-sample RMSE across the 3 years for both the west and east regions (Table 2). Using the mean of the values from the preceding year was considerably more accurate in predicting next-year observations than using the minimum value across the district in the preceding year.

We also compared values produced by the geostatistical ensemble model for the current year, in districts that had no test results in that year, to the observed data for the next year. The out-of-sample RMSE values obtained overlap with those obtained

across districts that did have susceptibility test data available for the preceding year (Table 2).

These results demonstrate that predictions from the geostatistical ensemble model provide more reliable up-to-date estimates of resistance 1 year after data collection compared to predictions from simple district-level data summaries, and can predict mortality in districts where no recent susceptibility test data are available.

Dissemination. The stratified maps presented here and the fine resolution mean mortality maps from Hancock et al. (6) for the years 2005 to 2017 are available to view and download on the IR Mapper website. These maps can be viewed on the IR Mapper website alongside the susceptibility test results for the years closest to that being modeled. Users can also choose to view each of these maps overlaid with the most recent data for both *An. gambiae* s.l. and *An. funestus*, as well as other vectors. They can zoom into their geographic region of interest and export the map image they have constructed.

IR Mapper is currently supported by a net manufacturer, Vestergaard SA, and the data in IR Mapper are managed through a partnership with the Kenya Medical Research Institute. This study did not use IR Mapper data for the work

Table 2. Comparing the accuracy of next-year predictions

Next year	RMSE		
	Ensemble model fit to surveillance data up to preceding year	Mean value of surveillance data from preceding year	Minimum value of surveillance data from preceding year
Data available in preceding year			
West region			
2015	0.224 (<i>n</i> = 149)	0.232 (<i>n</i> = 149)	0.386 (<i>n</i> = 149)
2016	0.239 (<i>n</i> = 129)	0.276 (<i>n</i> = 129)	0.309 (<i>n</i> = 129)
2017	0.302 (<i>n</i> = 243)	0.384 (<i>n</i> = 243)	0.50 (<i>n</i> = 243)
East region			
2015	0.186 (<i>n</i> = 159)	0.194 (<i>n</i> = 159)	0.301 (<i>n</i> = 159)
2016	0.276 (<i>n</i> = 85)	0.281 (<i>n</i> = 85)	0.298 (<i>n</i> = 85)
2017	0.277 (<i>n</i> = 68)	0.323 (<i>n</i> = 68)	0.395 (<i>n</i> = 68)
Data not available in preceding year			
West region			
2015	0.315 (<i>n</i> = 93)	No data	No data
2016	0.327 (<i>n</i> = 102)	No data	No data
2017	No data	No data	No data
East region			
2015	0.218 (<i>n</i> = 88)	No data	No data
2016	0.270 (<i>n</i> = 70)	No data	No data
2017	0.289 (<i>n</i> = 75)	No data	No data

The RMSE of predicted and observed next-year resistance where all data obtained after the given year were withheld from the prediction methods. A lower RMSE indicates a more accurate prediction. Observed datasets consisted of all pyrethroid susceptibility test results (performed using α -cypermethrin, deltamethrin, permethrin, and λ -cyhalothrin) from the next year for districts where test results for the preceding year were available. *n* is the number of withheld data points. The RMSE values shown in bold indicate the best-performing model for each year where multiple options are presented.

described in *Materials and Methods* and *Results*; however, data from both IR Mapper and WHO are presented in the Introduction, alongside the published data that we used in this study, to illustrate the gaps in the available insecticide resistance data whatever source is used.

The data files behind the stratified maps constructed during this study are also available from Figshare (<https://doi.org/10.6084/m9.figshare.12435248>).

Discussion

Here we provide maps that show the probability that the mean prevalence of pyrethroid resistance in a district meets a set of thresholds linked to specific malaria vector control recommendations. This information has not previously been provided for regions with data gaps in space and time. Assessing the level of insecticide resistance is essential in order to prioritize use of products that mitigate against it (7, 8, 23, 24). The new mixed formulation malaria vector control products are more expensive to produce, and funds for malaria control are limited. Past experience with IRS has shown that a switch to a more expensive product can reduce the coverage achieved, and reductions in IRS coverage have been linked to resurgences in malaria (25). It is therefore vital to have information such as the maps presented here that aids decisions on when and where more expensive products that mitigate against insecticide resistance are deployed (26, 27). The geostatistical ensemble model that we used has previously been shown to provide robust estimates within the area and time frame for which sparse data on pyrethroid resistance are available (6). Here we have shown that it provides the most robust predictions for the next year, in a scenario where no data for that year are available, compared to taking the mean or minimum value of the surveillance data for the preceding year. Similar results were also obtained when no data were available for the preceding year either. These results indicate that this approach can, in part, mitigate for the issue of a time lag between

vector sampling and data being available, for instances where the lag is up to 1 year. This approach will become less robust the longer the time lag is and the geostatistical ensemble model cannot compensate for a lack of continued field data collection (28).

Susceptibility test data are noisy (29, 30) and the low data volumes typically seen in resistance monitoring (Fig. 1) are particularly susceptible to issues of data noise. The model used here has the advantage that it separates the signal (trends in space and time) from this noise to provide mean mortality values, and this also has a smoothing effect seen in the fine resolution maps generated by Hancock et al. (6). The maps presented here were smoothed further by generating a set of district-wide means, and further still by setting a threshold mortality value. This results in contiguous areas that have the same resistance classification and do not always match the variation seen in the raw surveillance data, which may be the result of issues with sparse data and underlying data noise (31).

The maps presented here show the probability of resistance to deltamethrin in the *An. gambiae* species complex at a district level. The data that went into these maps were from mosquito samples representative of the *An. gambiae* species complex at each time and place, and thus the maps represent resistance in the species complex at each time and place including variation caused by the combination of spatially varying species composition and differences in resistance among these species (6, 15). Other species are important, notably *An. funestus* (32–34), and use of these maps needs to be accompanied by knowledge of the locally important vectors. Ideally, decisions made using information on resistance in *An. gambiae* s.l. should also be informed by information on the relative abundance of *An. gambiae* s.l. and *An. funestus*, and any other locally important vectors. The relative abundance of these vectors has been mapped across Africa by a previous study, which showed that insecticide-treated net and IRS use affect the relative abundance of these species (35).

Variation in the behavior of these vectors also influences how likely it is that they come into contact with indoors, insecticide-based interventions and, ideally, this variable should also be considered alongside insecticide resistance (36–39).

The maps presented here also focused on a single pyrethroid, deltamethrin. Predictions are available for α -cypermethrin, permethrin, and λ -cyhalothrin, and maps showing the probability of meeting key thresholds can also be generated for these pyrethroids. It is, however, important to note that previous work has shown strong associations among patterns of resistance to these four insecticides and evidence of resistance to one is likely to indicate resistance to the others (21). District-level maps of resistance were chosen to match the spatial resolution currently commonly used for operational decisions, but finer-resolution data may increasingly be used by decision makers in the future and the probability maps presented here can be generated down to a ~5-km resolution.

Recommendations for the deployment of PBO-treated nets are based on evidence for the mechanism of resistance as well as the level of resistance indicated by susceptibility tests (11). The most commonly available standardized data for cytochrome P450-mediated mechanisms of resistance are susceptibility tests using the PBO synergist (15, 40). More data would be required to generate predictive maps from synergist test results; however, the data review presented here poses the question of whether the benefit of having comprehensive synergist surveillance data are worth the cost of collecting such data. Here we have shown that the vast majority of locations tested are classified as having cytochrome P450-mediated pyrethroid resistance, as currently defined by WHO using synergist bioassays (12). Biochemical tests are also available, but they do not perform consistently. Genetic tests give more robust results but are expensive to perform and data are therefore even more sparse. The data that are available from genetic tests do, however, show the same trends as seen for the synergist bioassay results (40).

The Malaria Threats website also presents evidence for whether the criteria for deployment of PBO-treated nets have been met. On this website, data of unknown collection date are presented at point locations, rather than districts, although the locations shown may include centroids of districts and provinces as well as precisely located sampling sites. Each location is categorized as either 1) all criteria met, 2) at least one criterion is not met, or 3) more data are needed. Presumably class 2 includes instances where either pyrethroid mortality is <10% or >80%, or where an absence of cytochrome P450-mediated mechanisms of resistance has been confirmed, although we have shown here that evidence for absence of this mechanism is often contradicted by evidence for presence. The majority of locations shown on the Malaria Threats website, viewed on 1 June 2020, were classified as “more data needed,” again highlighting the gaps in the available data (*SI Appendix*, Fig. S3). The Malaria Threats site shows class 1 locations are most common in west Africa and least common in the southern part of east Africa, in agreement with our results. The two approaches may not, however, always provide consistent results in the future, which highlights the importance of sharing the data used by both approaches, with full details of the data sources, so that contradictory results can be interrogated (15, 41).

As new evidence becomes available, many of the key definitions and thresholds that are currently recommended by the

Global Plan for IRM and the Conditions for Deployment of PBO-treated Nets may be updated. The results here provide examples based on the currently recommended threshold values; however, the approach taken by our study is flexible and *SI Appendix* provides maps that use a full range of mortality thresholds. In addition, current policies advise that if financial constraints mean that the guidelines cannot be followed without compromising intervention coverage then the worst-affected areas should be targeted. Our mean and minimum predictive value maps (Fig. 2 *A* and *B*), the sliding scale of mortality thresholds (*SI Appendix*), and the continuous scale of probabilities for defined thresholds (Fig. 2 *C* and *D* and *SI Appendix*) all allow users to identify such areas.

The current results are of relevance in areas where IRS is the primary intervention. In these areas, the Global Plan for IRM also recommends preemptive use of rotations regardless of available data on insecticide resistance but warns against making a change if it would result in reduced coverage. The cheapest insecticides are currently pyrethroids and DDT; however, cross-resistance between these two classes means that use of one can lead to resistance to the other, reducing the classes available for rotation. This means that a rotation of classes that avoids issues of pyrethroid resistance requires more expensive compounds. Despite well-reported increases in insecticide resistance, the practice of using the same insecticide class for IRS in consecutive years is still common (20). The results presented here allow groups that are deploying IRS to identify areas where pyrethroid resistance is highest to target focal use of rotations using more expensive insecticides. The same approach can be taken in areas that primarily rely on LLINs, to introduce focal IRS or LLINs treated with a nonpyrethroid active ingredient, in areas with the highest resistance.

Ultimately, decisions on which intervention to use, and which insecticide to select if applicable, depend on multiple entomological, ecological, economic, epidemiological, cultural, and operational considerations (3). Future work should address this complexity using a hierarchical decision tree-based system, to simplify and standardize evidence-based decision making. Evidence of insecticide resistance and an increase in malaria cases are particularly important considerations for any such decision tree. Here we have focused on the prevalence of insecticide resistance and provide maps that can be used within a broader decision-making framework. The results generated by this study are freely available for use by all groups as stand-alone tools via the IR Mapper website or they can be obtained from Figshare for integration into more complex decision-making tools.

Data Availability. The data generated by this study have been deposited at Figshare, <https://doi.org/10.6084/m9.figshare.12435248>. The data that we used in our analyses were previously released at Figshare, <https://doi.org/10.6084/m9.figshare.9912623>, and the Dryad Digital Repository, <https://doi.org/10.5061/dryad.dn4676s>.

ACKNOWLEDGMENTS. We gratefully acknowledge helpful discussions with Tessa Knox, Lucía Fernández Montoya, Abdisalan Noor, and Jan Kolaczinski at the Global Malaria Programme of the World Health Organization and Seth Irish at the President’s Malaria Initiative. This work was funded by Wellcome Trust Grant 108440/Z/15/Z (to C.L.M.).

1. S. Bhatt *et al.*, The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. *Nature* **526**, 207–211 (2015).
2. J. Hemingway, Resistance: A problem without an easy solution. *Pestic. Biochem. Physiol.* **151**, 73–75 (2018).
3. World Health Organization, *Global Plan for Insecticide Resistance Management in Malaria Vectors*, (World Health Organization, Geneva, 2012).
4. World Health Organization, *Prequalified Lists: Vector Control Products*, (World Health Organization, Geneva, 2019).
5. World Health Organization, *Guidelines for Malaria Vector Control*, (World Health Organization, Geneva, 2019).
6. P. A. Hancock *et al.*, Mapping trends in insecticide resistance phenotypes in African malaria vectors. *PLoS Biol.* **18**, e3000633 (2020).
7. C. Ngufor *et al.*, Which intervention is better for malaria vector control: Insecticide mixture long-lasting insecticidal nets or standard pyrethroid nets combined with indoor residual spraying? *Malar. J.* **16**, 340 (2017).

8. A. B. Tiono *et al.*, Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: A cluster-randomised controlled trial. *Lancet* **392**, 569–580 (2018).
9. K. Gleave, N. Lissenden, M. Richardson, L. Choi, H. Ranson, Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa. *Cochrane Database Syst. Rev.* **11**, CD012776 (2018).
10. World Health Organization, *Conditions for Deployment of Mosquito Nets Treated with a Pyrethroid and Piperonyl Butoxide*, (World Health Organization, Geneva, 2017).
11. T. S. Churcher, N. Lissenden, J. T. Griffin, E. Worrall, H. Ranson, The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa. *eLife* **5**, 16090 (2016).
12. World Health Organization, *Test Procedures for Insecticide Resistance Monitoring in Malaria Vector Mosquitoes*, (World Health Organization, Geneva, 2016).
13. W. G. Brogden, A. Chan, *Guidelines for Evaluating Insecticide Resistance in Vectors Using the CDC Bottle Bioassay*, (Centers for Disease Control and Prevention, Atlanta, GA, 1998).
14. A. P. Mnzava *et al.*, Implementation of the global plan for insecticide resistance management in malaria vectors: Progress, challenges and the way forward. *Malar. J.* **14**, 173 (2015).
15. C. L. Moyes *et al.*, Analysis-ready datasets for insecticide resistance phenotype and genotype frequency in African malaria vectors. *Sci. Data* **6**, 121 (2019).
16. World Health Organization, Malaria threats map. <http://apps.who.int/malaria/maps/threats/>. Accessed 9 December 2019.
17. KEMRI-CGHR, Vestergaard, and ESRI Eastern Africa, IR Mapper. <https://www.irmapper.com/>. Accessed 9 December 2019.
18. S. Bhatt *et al.*, Coverage and system efficiencies of insecticide-treated nets in Africa from 2000 to 2017. *eLife* **4**, e09672 (2015).
19. C. M. J. Hendriks *et al.*, Mapping geospatial processes affecting the environmental fate of agricultural pesticides in Africa. *Int. J. Environ. Res. Public Health* **16**, 3523 (2019).
20. J. A. A. Tangena *et al.*, Indoor residual spraying for malaria control in sub-Saharan Africa 1997 to 2017: An adjusted retrospective analysis. *Malar. J.* **19**, 150 (2020).
21. P. A. Hancock *et al.*, Associated patterns of insecticide resistance in field populations of malaria vectors across Africa. *Proc. Natl. Acad. Sci. U.S.A.* **115**, 5938–5943 (2018).
22. A. Wiebe *et al.*, Geographical distributions of African malaria vector sibling species and evidence for insecticide resistance. *Malar. J.* **16**, 85 (2017).
23. V. Corbel *et al.*, Field efficacy of a new mosaic long-lasting mosquito net (PermaNet 3.0) against pyrethroid-resistant malaria vectors: A multi centre study in Western and Central Africa. *Malar. J.* **9**, 113 (2010).
24. N. Protopopoff *et al.*, Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: A cluster, randomised controlled, two-by-two factorial design trial. *Lancet* **391**, 1577–1588 (2018).
25. R. M. Oxborough, Trends in US President's malaria initiative-funded indoor residual spray coverage and insecticide choice in sub-Saharan Africa (2008-2015): Urgent need for affordable, long-lasting insecticides. *Malar. J.* **15**, 146 (2016).
26. O. J. T. Briët *et al.*, Effects of pyrethroid resistance on the cost effectiveness of a mass distribution of long-lasting insecticidal nets: A modelling study. *Malar. J.* **12**, 77 (2013).
27. E. Sherrard-Smith *et al.*, Systematic review of indoor residual spray efficacy and effectiveness against *Plasmodium falciparum* in Africa. *Nat. Commun.* **9**, 4982 (2018).
28. G. F. Killeen, P. P. Chaki, T. E. Reed, C. L. Moyes, N. J. Govella, "Entomological surveillance as a cornerstone of Malaria elimination: A critical appraisal" in *Towards Malaria Elimination—A Leap Forward*, V. Dev, S. Manguin, Eds. (InTech Open, London, 2018), pp. 403–429.
29. K. D. Glunt, S. V. Oliver, R. H. Hunt, K. P. Paaijmans, The impact of temperature on insecticide toxicity against the malaria vectors *Anopheles arabiensis* and *Anopheles funestus*. *Malar. J.* **17**, 131 (2018).
30. H. F. Owusu, N. Chitnis, P. Müller, Insecticide susceptibility of *Anopheles* mosquitoes changes in response to variations in the larval environment. *Sci. Rep.* **7**, 3667 (2017).
31. A. P. Patil, P. W. Gething, F. B. Piel, S. I. Hay, Bayesian geostatistics in health cartography: The perspective of malaria. *Trends Parasitol.* **27**, 246–253 (2011).
32. R. Djouaka *et al.*, Multiple insecticide resistance in an infected population of the malaria vector *Anopheles funestus* in Benin. *Parasit. Vectors* **9**, 453 (2016).
33. J. M. Riveron *et al.*, Rise of multiple insecticide resistance in *Anopheles funestus* in Malawi: A major concern for malaria vector control. *Malar. J.* **14**, 344 (2015).
34. M. Okia *et al.*, Insecticide resistance status of the malaria mosquitoes: *Anopheles gambiae* and *Anopheles funestus* in eastern and northern Uganda. *Malar. J.* **17**, 157 (2018).
35. M. E. Sinka *et al.*, Modelling the relative abundance of the primary African vectors of malaria before and after the implementation of indoor, insecticide-based vector control. *Malar. J.* **15**, 142 (2016).
36. G. F. Killeen *et al.*, Going beyond personal protection against mosquito bites to eliminate malaria transmission: Population suppression of malaria vectors that exploit both human and animal blood. *BMJ Glob. Health* **2**, e000198 (2017).
37. E. Sherrard-Smith *et al.*, Mosquito feeding behavior and how it influences residual malaria transmission across Africa. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 15086–15095 (2019).
38. N. C. Massey *et al.*, A global bionomic database for the dominant vectors of human malaria. *Sci. Data* **3**, 160014 (2016).
39. S. L. Wu *et al.*, Vector bionomics and vectorial capacity as emergent properties of mosquito behaviors and ecology. *PLoS Comput. Biol.* **16**, e1007446 (2020).
40. M. Coleman *et al.*, Developing global maps of insecticide resistance risk to improve vector control. *Malar. J.* **16**, 86 (2017).
41. C. L. Moyes, W. H. Temperley, A. J. Henry, C. R. Burgert, S. I. Hay, Providing open access data online to advance malaria research and control. *Malar. J.* **12**, 161 (2013).